For Immediate Release
Company name: DAIICHI SANKYO COMPANY, LIMITED
Representative: Joji Nakayama, President and CEO
(Code no.: 4568, First Section of Tokyo, Osaka and Nagoya Stock Exchanges)
Please address inquiries to Toshiaki Sai, Corporate Officer,
Vice President, Corporate Communications Department
Telephone: +81-3-6225-1126 (Public Relations)
+81-3-6225-1125 (Investor Relations)
http://www.daiichisankyo.com/
Revision of Earnings Forecasts
Tokyo, Japan (August 31, 2010) –Daiichi Sankyo Company, Limited (hereafter, the Company) today announced a revision of its consolidated earnings forecasts for the first six months of the fiscal year ending March 2011 (hereafter, FY2010), which was announced on July 30, 2010, in light of recent trends in operating performance.
Revision of Earnings Forecasts
1. Revision of consolidated earnings forecasts for the first six months of FY2010
(From April 1, 2010 to September 30, 2010)
| |
Net sales
(Millions of yen) |
Operating income
(Millions of yen) |
Ordinary income
(Millions of yen) |
Net income
(Millions of yen) |
Net income per share
(Yen) |
| Previous forecasts (A) |
490,000 |
50,000 |
48,000 |
25,000 |
35.52 |
| Revised forecasts (B) |
495,000 |
70,000 |
70,000 |
33,000 |
46.88 |
| Change (B-A) |
5,000 |
20,000 |
22,000 |
8,000 |
|
| Percentage of change (%) |
1.0 |
40.0 |
45.8 |
32.0 |
|
(Reference)
Results of the first six months of the previous fiscal year |
470,568 |
50,850 |
52,259 |
18,691 |
26.55 |
2.Main reasons of the revision
With regard to the net sales in the consolidated earnings forecasts for the first six months of FY2010 (from April 1, 2010 to September 30, 2010), despite the decrease in sales at U.S. and European subsidiaries following the rising yen, thanks to the more-than-expected sales of the antiviral drug valacyclovir in the U.S. by Ranbaxy Laboratories Limited (hereafter, Ranbaxy), which recently announced its financial results for the first six months, the Company revised its forecasts upwards.
With respect to profits, in addition to the increased sales at Ranbaxy, major processing of expenditures being postponed to the third quarter or later, operating income, ordinary income and net income are expected to exceed the previous forecasts.
The consolidated earnings forecasts for the full fiscal year remain unchanged from the previously announced forecasts.
The forecasted statements shown above are based on information currently available and certain assumptions that the Company regards as reasonable. Actual performance and other results may differ materially from these forecasted figures due to various factors.
End